Klaria partners with RTHS to develop early migraine detection technology

• Klaria Pharma entered a collaboration with Gothenburg-based RTHS to develop earlier migraine detection and earlier treatment.
• RTHS will use non-invasive sensors and algorithms tracking blood-flow dynamics to flag migraine attacks before symptoms start.
• Klaria’s EU-cleared Sumatriptan Alginate Film is positioned as the rapid, on-demand treatment paired with earlier attack detection.
• Partnership aims to improve attack control, support more consistent acute treatment, reduce progression risk toward chronic migraine.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klaria Pharma Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 202609071411BITN____UKPR__SV_20260907-BIT-7394-0) on September 07, 2026, and is solely responsible for the information contained therein.